200 related articles for article (PubMed ID: 27563438)
1. Continuation of trastuzumab beyond disease progression in HER2-positive metastatic gastric cancer: the MD Anderson experience.
Al-Shamsi HO; Fahmawi Y; Dahbour I; Tabash A; Rogers JE; Mares JE; Blum MA; Estrella J; Matamoros A; Sagebiel T; Devine CE; Badgwell BD; Lin QD; Das P; Ajani JA
J Gastrointest Oncol; 2016 Aug; 7(4):499-505. PubMed ID: 27563438
[TBL] [Abstract][Full Text] [Related]
2. In era of immunotherapy: the value of trastuzumab beyond progression in patients with trastuzumab-resistant HER2-positive advanced or metastatic gastric cancer.
Wang H; Nie C; Xu W; Li J; Gou H; Lv H; Chen B; Wang J; Liu Y; He Y; Zhao J; Chen X
Therap Adv Gastroenterol; 2024; 17():17562848241245455. PubMed ID: 38617123
[TBL] [Abstract][Full Text] [Related]
3. Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group.
Fountzilas G; Razis E; Tsavdaridis D; Karina M; Labropoulos S; Christodoulou C; Mavroudis D; Gogas H; Georgoulias V; Skarlos D
Clin Breast Cancer; 2003 Jun; 4(2):120-5. PubMed ID: 12864940
[TBL] [Abstract][Full Text] [Related]
4. Correlation between human epidermal growth factor receptor 2 expression level and efficacy of trastuzumab beyond progression in metastatic gastric cancer.
Narita Y; Kadowaki S; Masuishi T; Taniguchi H; Takahari D; Ura T; Ando M; Tajika M; Niwa Y; Eto T; Hara H; Asayama M; Yamaguchi K; Yatabe Y; Muro K
Oncol Lett; 2017 Aug; 14(2):2545-2551. PubMed ID: 28781693
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of trastuzumab combined with chemotherapy for first-line treatment and beyond progression of HER2-overexpressing advanced breast cancer.
Li H; Shao B; Yan Y; Song G; Liu X; Wang J; Liang X
Chin J Cancer Res; 2016 Jun; 28(3):330-8. PubMed ID: 27478318
[TBL] [Abstract][Full Text] [Related]
6. Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up.
Wang R; Smyth LM; Iyengar N; Chandarlapaty S; Modi S; Jochelson M; Patil S; Norton L; Hudis CA; Dang CT
Oncologist; 2019 Aug; 24(8):e646-e652. PubMed ID: 30602614
[TBL] [Abstract][Full Text] [Related]
7. Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study.
Palle J; Tougeron D; Pozet A; Soularue E; Artru P; Leroy F; Dubreuil O; Sarabi M; Williet N; Manfredi S; Martin-Babau J; Rebischung C; Abdelghani MB; Evesque L; Dreanic J; Hautefeuille V; Louafi S; Sefrioui D; Savinelli F; Mabro M; Rousseau B; Lecaille C; Bouché O; Louvet C; Lecomte T; Bonnetain F; Taieb J; Zaanan A
Oncotarget; 2017 Nov; 8(60):101383-101393. PubMed ID: 29254172
[TBL] [Abstract][Full Text] [Related]
8. Phase II clinical trial of second-line weekly paclitaxel plus trastuzumab for patients with HER2-positive metastatic gastric cancer.
Horita Y; Nishino M; Sugimoto S; Kida A; Mizukami A; Yano M; Arihara F; Matsuda K; Matsuda M; Sakai A
Anticancer Drugs; 2019 Jan; 30(1):98-104. PubMed ID: 30124494
[TBL] [Abstract][Full Text] [Related]
9. Prolonged survival of patients receiving trastuzumab beyond disease progression for HER2 overexpressing metastatic breast cancer (MBC).
Stemmler HJ; Kahlert S; Siekiera W; Untch M; Heinrich B; Heinemann V
Onkologie; 2005 Nov; 28(11):582-6. PubMed ID: 16249644
[TBL] [Abstract][Full Text] [Related]
10. HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer.
Kim JW; Kim JH; Im SA; Kim YJ; Han HS; Kim JS; Lee KH; Kim TY; Han SW; Jeon YK; Oh DY; Kim TY; Park IA
Cancer Chemother Pharmacol; 2013 Jul; 72(1):109-15. PubMed ID: 23673443
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of late line pertuzumab with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer: An Australian case series.
Bergin ART; Luen SJ; Savas P; Boolell V; Cho D; Lynch J; Nott L; Stuart-Harris R; Teo LN; Yap SY; Loi S
Asia Pac J Clin Oncol; 2019 Dec; 15(6):377-382. PubMed ID: 31321873
[TBL] [Abstract][Full Text] [Related]
12. [Clinical value of trastuzumab in the treatment of lapatinib-resistant HER2-positive metastatic breast cancer].
Ma F; Xu BH; Li HH; Li Q; Zhang P; Yuan P; Wang JY; Fan Y; Li Q
Zhonghua Zhong Liu Za Zhi; 2013 Jul; 35(7):521-4. PubMed ID: 24257305
[TBL] [Abstract][Full Text] [Related]
13. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2.
McKeage K; Perry CM
Drugs; 2002; 62(1):209-43. PubMed ID: 11790161
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer.
Yeo W; Luk MY; Soong IS; Yuen TY; Ng TY; Mo FK; Chan K; Wong SY; Tsang J; Leung C; Suen JJ; Ngan RK
Hong Kong Med J; 2018 Feb; 24(1):56-62. PubMed ID: 29326401
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study.
Soularue É; Cohen R; Tournigand C; Zaanan A; Louvet C; Bachet JB; Hentic O; Samalin E; Chibaudel B; de Gramont A; André T;
Bull Cancer; 2015 Apr; 102(4):324-31. PubMed ID: 25744576
[TBL] [Abstract][Full Text] [Related]
16. Continuation of trastuzumab beyond progression in HER2-positive advanced esophagogastric cancer: a meta-analysis.
Ter Veer E; van den Ende T; Creemers A; de Waal L; van Oijen MGH; van Laarhoven HWM
Acta Oncol; 2018 Dec; 57(12):1599-1604. PubMed ID: 30264641
[TBL] [Abstract][Full Text] [Related]
17. Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial.
Liu T; Qin Y; Li J; Xu R; Xu J; Yang S; Qin S; Bai Y; Wu C; Mao Y; Wu H; Ge Y; Shen L
Cancer Commun (Lond); 2019 Jun; 39(1):38. PubMed ID: 31234927
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study.
Meulendijks D; Beerepoot LV; Boot H; de Groot JW; Los M; Boers JE; Vanhoutvin SA; Polee MB; Beeker A; Portielje JE; de Jong RS; Goey SH; Kuiper M; Sikorska K; Beijnen JH; Tesselaar ME; Schellens JH; Cats A
Invest New Drugs; 2016 Feb; 34(1):119-28. PubMed ID: 26643663
[TBL] [Abstract][Full Text] [Related]
19. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer.
Miller K; Cortes J; Hurvitz SA; Krop IE; Tripathy D; Verma S; Riahi K; Reynolds JG; Wickham TJ; Molnar I; Yardley DA
BMC Cancer; 2016 Jun; 16():352. PubMed ID: 27259714
[TBL] [Abstract][Full Text] [Related]
20. Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial.
Gong J; Liu T; Fan Q; Bai L; Bi F; Qin S; Wang J; Xu N; Cheng Y; Bai Y; Liu W; Wang L; Shen L
BMC Cancer; 2016 Feb; 16():68. PubMed ID: 26857702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
